Medtech Firm Nativis Appoints Ferguson Chief Scientific Officer

Xconomy Seattle — 

Nativis, a medical device company aiming to use ultra-low radio frequency energy to treat disease, has appointed Kenneth Ferguson chief scientific officer. Seattle-based Nativis is currently in clinical trials testing its medical device, Nativis Voyager, as a treatment for recurrent glioblastoma, a form of brain cancer. Before joining Nativis, Ferguson was chief development officer for Seattle biotech Omeros (NASDAQ: OMER). His experience also includes executive roles at VacTX and Icos, now a subsidiary of Eli Lilly (NYSE: LLY).